• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨折住院后基层医疗开具抗骨质疏松症类药物处方情况。

Primary-care prescribing of anti-osteoporotic-type medications following hospitalisation for fractures.

机构信息

Department of Pharmacology & Therapeutics, Trinity Centre for Health Sciences, St. James's Hospital, Dublin 8, Ireland.

出版信息

Eur J Clin Pharmacol. 2011 Mar;67(3):301-8. doi: 10.1007/s00228-010-0942-y. Epub 2010 Nov 23.

DOI:10.1007/s00228-010-0942-y
PMID:21104407
Abstract

PURPOSE

We examined the prescribing of antiosteoporotic medications pre- and post hospital admission in patients with fragility fractures as well as factors associated with prescribing of these treatments following admission.

METHODS

We identified all patients aged ≥ 55 years at a large teaching hospital between 2005 and 2008 with a fracture using the Hospital In-Patient Enquiry (HIPE) system. These data were linked to prescribing data from the Health Service Executive Primary Care Reimbursement Services (HSE-PCRS) scheme before and after discharge (821 patients). Logistic regression analysis was used to examine the likelihood of prescription of antiosteoporotic medication pre- and post discharge in relation to year of discharge, age, gender, and type of fracture.

RESULTS

Prescribing of antiosteoporotic treatment before fracture increased from 2.6% [95% confidence interval (CI) 2.23-2.93%] in 2005 to 10.6% (95% CI 9.32-11.86) by 2008, whereas post fracture prescribing increased from 11% (95% CI 9.64-12.36) to 47% (95% CI 43.6-50.3). In patients discharged from hospital in 2007, postfracture prescribing was 31.8% (95% CI 28.66-35.02) at 12 months, increasing to 50.3% (95% CI 46.6-53.9) at 24 months. The highest rate of prescribing was in the 65- to 69-year age group [odds ratio (OR) 8.51, 95% CI 1.75-41.35]. Patients discharged in 2008 were eight times more likely to be treated than patients discharged in 2005 (OR 8.01, 95% CI 4.55-14.09).

CONCLUSION

The percentage of patients on antiosteoporotic treatment post fracture increased significantly from 2005 to 2008. This may be largely due to the introduction of the Osteoporosis Clinic to the hospital in 2005.

摘要

目的

我们研究了脆性骨折患者住院前后抗骨质疏松药物的开具情况,以及与住院后这些治疗方案开具相关的因素。

方法

我们通过医院住院查询系统(HIPE),确定了 2005 年至 2008 年期间一家大型教学医院所有年龄≥55 岁的骨折患者。这些数据与出院前后(821 例患者)卫生服务管理局初级保健报销服务(HSE-PCRS)方案的处方数据相关联。我们采用逻辑回归分析,研究了与出院年份、年龄、性别和骨折类型相关的出院前后开具抗骨质疏松药物的可能性。

结果

骨折前抗骨质疏松治疗的开具率从 2005 年的 2.6%(95%可信区间[CI]2.23%-2.93%)增加到 2008 年的 10.6%(95% CI 9.32%-11.86%),而骨折后开具率从 11%(95% CI 9.64%-12.36%)增加到 47%(95% CI 43.6%-50.3%)。2007 年出院的患者,骨折后开具率在 12 个月时为 31.8%(95% CI 28.66%-35.02%),24 个月时增至 50.3%(95% CI 46.6%-53.9%)。开具率最高的是 65-69 岁年龄组[优势比(OR)8.51,95% CI 1.75-41.35]。与 2005 年出院的患者相比,2008 年出院的患者接受治疗的可能性增加了 8 倍(OR 8.01,95% CI 4.55-14.09)。

结论

从 2005 年到 2008 年,骨折后接受抗骨质疏松治疗的患者比例显著增加。这可能主要归因于 2005 年医院开设了骨质疏松症诊所。

相似文献

1
Primary-care prescribing of anti-osteoporotic-type medications following hospitalisation for fractures.骨折住院后基层医疗开具抗骨质疏松症类药物处方情况。
Eur J Clin Pharmacol. 2011 Mar;67(3):301-8. doi: 10.1007/s00228-010-0942-y. Epub 2010 Nov 23.
2
Comparison of prescribing and adherence patterns of anti-osteoporotic medications post-admission for fragility type fracture in an urban teaching hospital and a rural teaching hospital in Ireland between 2005 and 2008.2005 年至 2008 年期间,爱尔兰一所城市教学医院和一所农村教学医院中,脆性骨折患者入院后抗骨质疏松药物的开具和依从性模式比较。
Ir J Med Sci. 2013 Dec;182(4):601-8. doi: 10.1007/s11845-013-0935-9. Epub 2013 Mar 13.
3
Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study.1999 - 2013年英国髋部骨折后二次骨折预防的地域差异研究
Osteoporos Int. 2017 Jan;28(1):169-178. doi: 10.1007/s00198-016-3811-4. Epub 2016 Nov 3.
4
Prescription of anti-osteoporosis medications after hospitalization for hip fracture: a multicentre Italian survey.髋部骨折住院后抗骨质疏松药物的处方:一项意大利多中心调查
Aging Clin Exp Res. 2017 Oct;29(5):1031-1037. doi: 10.1007/s40520-016-0681-8. Epub 2016 Dec 9.
5
Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice.质子泵抑制剂在一般实践中使用后抗骨质疏松治疗的处方。
Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):763-9. doi: 10.1002/pds.1972.
6
Undertreatment with anti-osteoporotic drugs after hospitalization for fracture.骨折住院后抗骨质疏松药物治疗不足。
Osteoporos Int. 2004 Feb;15(2):120-4. doi: 10.1007/s00198-003-1544-7. Epub 2003 Nov 13.
7
Declining trend in osteoporosis management and screening following vertebral compression fractures - a national analysis of commercial insurance and medicare advantage beneficiaries.骨质疏松症管理和筛查在椎体压缩性骨折后的下降趋势 - 商业保险和医疗保险优势受益人的全国分析。
Spine J. 2020 Apr;20(4):538-546. doi: 10.1016/j.spinee.2019.10.020. Epub 2019 Nov 1.
8
Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China.2010-2016 年中国福建骨质疏松性骨折后抗骨质疏松药物治疗模式。
Arch Osteoporos. 2020 Aug 20;15(1):134. doi: 10.1007/s11657-020-00798-1.
9
Improving community prescribing of post-fracture denosumab after discharge.改善出院后骨折后地诺单抗的社区处方情况。
Br J Hosp Med (Lond). 2017 Jan 2;78(1):20-22. doi: 10.12968/hmed.2017.78.1.20.
10
Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture.髋部骨折住院患者骨质疏松治疗的错失机会。
J Am Geriatr Soc. 2010 Apr;58(4):650-7. doi: 10.1111/j.1532-5415.2010.02769.x.

引用本文的文献

1
Disparities in osteoporosis treatments.骨质疏松症治疗方面的差异。
Osteoporos Int. 2016 Feb;27(2):509-19. doi: 10.1007/s00198-015-3249-0. Epub 2015 Jul 28.
2
Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.骨质疏松性骨折女性的骨折后药物治疗:美国一个管理式医疗人群的分析
Osteoporos Int. 2014 Dec;25(12):2777-86. doi: 10.1007/s00198-014-2827-x. Epub 2014 Aug 12.
3
"Burden of osteoporotic fractures in primary health care in Catalonia (Spain): a population-based study".

本文引用的文献

1
The utilisation and expenditure of medicines for the prophylaxis and treatment of osteoporosis.用于骨质疏松症预防和治疗的药物的使用与支出。
Ir Med J. 2008 Feb;101(2):38-41.
2
Secondary prevention of fragility fractures by orthopaedic teams in the UK: a national survey.英国骨科团队对脆性骨折的二级预防:一项全国性调查。
Int J Clin Pract. 2008 Mar;62(3):382-7. doi: 10.1111/j.1742-1241.2007.01662.x. Epub 2008 Jan 8.
3
Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004.1995 - 2004年髋部骨折后骨质疏松症药物处方趋势
"西班牙加泰罗尼亚地区初级卫生保健中的骨质疏松性骨折负担:一项基于人群的研究"。
BMC Musculoskelet Disord. 2012 May 28;13:79. doi: 10.1186/1471-2474-13-79.
J Rheumatol. 2008 Feb;35(2):319-26. Epub 2007 Dec 1.
4
Successful direct intervention for osteoporosis in patients with minimal trauma fractures.对轻度创伤骨折患者骨质疏松症的成功直接干预。
Osteoporos Int. 2007 Dec;18(12):1633-9. doi: 10.1007/s00198-007-0418-9. Epub 2007 Jun 30.
5
Development of an integrated-care delivery model for post-fracture care in Ontario, Canada.加拿大安大略省骨折后护理综合医疗服务模式的发展
Osteoporos Int. 2006;17(9):1337-45. doi: 10.1007/s00198-006-0076-3. Epub 2006 Jul 4.
6
A randomized study of two different information-based interventions on the management of osteoporosis in minimal and moderate trauma fractures.一项关于两种不同基于信息的干预措施对轻度和中度创伤性骨折骨质疏松症管理效果的随机研究。
Osteoporos Int. 2006;17(9):1309-17. doi: 10.1007/s00198-006-0078-1. Epub 2006 Jun 21.
7
Diagnosis, screening, prevention, and treatment of osteoporosis.骨质疏松症的诊断、筛查、预防及治疗。
Mayo Clin Proc. 2006 May;81(5):662-72. doi: 10.4065/81.5.662.
8
Update of current therapeutic options for the treatment of postmenopausal osteoporosis.绝经后骨质疏松症治疗的当前治疗选择更新
Clin Ther. 2006 Feb;28(2):151-73. doi: 10.1016/j.clinthera.2006.02.007.
9
Fragility fractures and the osteoporosis care gap: an international phenomenon.脆性骨折与骨质疏松症护理缺口:一种国际现象。
Semin Arthritis Rheum. 2006 Apr;35(5):293-305. doi: 10.1016/j.semarthrit.2005.11.001.
10
Knowledge and opinions of orthopaedic surgeons concerning medical evaluation and treatment of patients with osteoporotic fracture.骨科医生关于骨质疏松性骨折患者医学评估与治疗的知识和观点。
J Bone Joint Surg Am. 2006 Jan;88(1):18-24. doi: 10.2106/JBJS.D.02949.